Refractory cancers
that defy research…

Meet a radical new way
of conducting clinical trials

Industry

Our fast-tracked molecular and genomic screening and patient enrolment from the entire nation are increasing clinical trial efficiency and reducing costs.

The approach to clinical trials is changing

Why work with Omico?

1

Make your trials cheaper and faster to run

2

Draw on national-scale screening of over 25,000 patients with advanced cancer

3

Identify the right patients and the right trials

4

Draw on the knowledge and expertise of our network

Our purpose with industry

Omico works with industry partners to advance precision oncology research, support biomarker-led clinical trials and help improve access to next-generation cancer therapies.

Through genomic and molecular screening, treatment matching, research collaboration and biomarker-led trials, we aim to:

stimulate research into the prevention, diagnosis and better management of cancers, particularly those with high unmet need
accelerate the transition from discovery to clinical application
support more efficient biomarker-led patient identification and trial enrolment, and site selection
help generate evidence that informs new standards of cancer care
improve opportunities for Australians living with cancer to access emerging therapies

National Reach

Working with Omico provides access to one of Australia’s largest precision oncology networks, including:

more than 25,000 patients screened through our initiatives, and growing
key opinion leaders and clinicians in oncology
a national network seeing over 20,000 people newly diagnosed with cancer each year
1,500+ researchers spanning discovery and clinical research

Proven Capability

An established molecular signal-seeking and drug development platform
High-throughput matching of patients to biomarker-led studies
Strengthen the innovation and efficiency of trial design, recruitment and completion
Access to biospecimens, translational research and scientific collaboration

Get in touch to advance research together

The Omico Advantage: how national-scale screening improves trial efficiency

Meet your clinical trial objectives sooner and for a lower cost with Omico.

Standard biomarker screening

Traditionally, biomarker screening is performed in each individual clinical trial. This inefficient method contributes significant costs to running a clinical trial, costing in the region of AUD $10M to identify 200 trial participants.

$500

per test

$50,000

per patient identified

200

specific biomakers per AUD $10M

Comprehensive genomic profiling

CGP is a next-generation screening approach that looks for hundreds of cancer biomarkers at the same time. This more efficient method costs in the region of AUD $10 M to identify 400 trial participants for multiple clinical trials, a significant cost saving.

$2,500

per test

$25,000

per patient identified

400

per patient identified

Meet your clinical trial objectives sooner and for a lower cost with Omico.

Let's connect